Neoleukin Therapeutics, Inc. announced the appointment of Donna M. Cochener as General Counsel, Senior Vice President Legal. Ms. Cochener joins Neoleukin after serving as Senior Vice President, Deputy General Counsel at HomeStreet, Inc. In that role, she was primarily responsible for securities reporting and compliance and corporate governance as well as serving as lead attorney on a range of transactions, including mergers and acquisitions and debt and equity financings.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.47 USD | -0.66% | +12.39% | +93.34% |
06-03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
06-03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+93.34% | 486M | |
+55.70% | 59.34B | |
+42.83% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neoleukin Therapeutics, Inc. Appoints Donna M. Cochener as General Counsel, Senior Vice President Legal